The optimum time to start ART in patients with HIV-associated TB is subject to a complex series of competing risks [94] and must balance the high risk of morbidity and mortality in patients with very low CD4 cell counts and severe disease with the potential occurrence of additive toxicities and immune reconstitution inflammatory syndrome (IRIS). The gene discussed is CD4; the disease is tuberculosis.